Skip to Main Content Skip to Site Map Skip to Accessibility Statement GLP-1 Receptor Agonists

There are currently very limited, intermittent supplies of all glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Supplies are not expected to stabilise to meet full market demand until at least December 2024. Please refer to GLP1 MSN for further information.

Daily Injection

Liraglutide (Victoza®) 6mg/ml solution for injection 3ml pre-filled pens

Prescribe by Brand Name

Weekly Injection

Dulaglutide (Trulicity®) 0.75mg/0.5ml, 1.5mg/0.5ml, 3mg/0.5ml, 4.5mg/0.5ml solution for injection pre-filled pens

Prescribe by Brand Name


Semaglutide (Ozempic®▼) 0.25mg/0.19ml, 0.5mg/0.37ml, 1mg/0.74ml solution for injection pre-filled pens

Prescribe by Brand Name

Oral tablets

Semaglutide (Rybelsus®▼) 3mg, 7mg 14mg tablets

Prescribe by Brand Name

Prescribing Notes

  • Prescribe as per NICE NG28 recommendations. See also NICE visual summary for blood glucose lowering therapy in adults with type 2 diabetes.
  • Stop DPP-4 inhibitor if initiating GLP-1 receptor agonist (the combination is unlikely to provide synergistic effects beyond monotherapy with either agent).
  • The formulary covers the use of GLP-1 receptor agonists in type 2 diabetes only. GLP-1 receptor agonists should not be prescribed for managing overweight and obesity until a specialist weight management service (tier 3) has been established. See correspondence for further details.
  • To prevent waste, please avoid prescribing large quantities. GLP-1 receptor agonists require refrigeration and are expensive. One month’s supply should be adequate for most patients – refer to GLP-1 agonists supplement for further details on appropriate quantities.
  • Stopping rules with GLP-1 receptor agonists: NICE state only continue GLP‑1 receptor agonist therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months).
  • Gastric emptying may be delayed, therefore the rate and extent of absorption of other oral drugs administered at the same time may be affected.
  • Doses of concomitant sulfonylurea may need to be reduced when a GLP-1 receptor agonist is started.
  • Upper gastrointestinal side effects such as nausea are common with GLP-1 receptor agonist therapy.
  • There are rare reports of acute pancreatitis in patients using these drugs. GLP-1 receptor agonists should be avoided in patients considered to be at high risk of pancreatitis. Patients and their carers should be told how to recognise signs and symptoms of pancreatitis.
  • Thyroid adverse events (including increased blood calcitonin, goitre and thyroid neoplasm) have been rarely reported in clinical trials with liraglutide, particularly in patients with pre-existing thyroid disease.


  • Diabetic ketoacidosis has been reported in patients with type 2 diabetes on a combination of a GLP-1 receptor agonist and insulin who had doses of concomitant insulin rapidly reduced or discontinued. See MHRA for further details.